Cartesian Therapeutic News Today

Cartesian Therapeutics, Inc. (NASDAQ:RNAC – Free Report) – Stock analysts at Leerink Partnrs boosted their Q2 2024 earnings estimates for Cartesian Therapeutics in a research note issued to investors on Wednesday, May 8th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($0.95) per share for the quarter, up from their prior […]

Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current standards. Analysts project substantial market capture and peak sales potential.

The chimeric antigen receptor T-cell therapy (CAR T) from Cabaletta Bio has already been cleared for trials in systemic lupus erythematosus, myositis, and systemic sclerosis.

Cary, NC (PRWEB) August 23, 2022 -- InstantGMP™ celebrates four years of proudly supporting Cartesian Therapeutics’ groundbreaking work in the field of RNA